Barrier-penetrating liposome targeted delivery of basic fibroblast growth factor for spinal cord injury repair. (February 2023)

• Record Type: Journal Article
• Authors: Wu, Fenzan; Wang, Penghui; Wei, Xiaojie; Yang, Yanhong; Al Mamun, Abdullah; Zhang, Xie; Zhu, Yunsen; Mo, Tingting; Zhang, Hongyu; Jiang, Chang; Hu, Jie; Xiao, Jian
• Is Part Of: Materials today bio. Volume 18(2023)
• Publication Date: 2023-02
• Subjects: Spinal cord injury -- Liposome -- Target -- Basic fibroblast growth factor -- Drug delivery; SCI Spinal cord injury -- BSCB Blood-spinal cord barrier -- bFGF Basic fibroblast growth factor -- CSPGs Chondroitin sulfate proteoglycans -- Cp CAQK peptide -- Rp R2KC peptide -- 1H NMR 1H Nuclear magnetic resonance -- Mal Maleimide -- FITC-BSA Fluorescein isothiocyanate-labeled bovine serum albumin -- CCK-8 Cell counting kit-8 -- HUVECs Human umbilical vein endothelial cells -- VEGF-A Vascular endothelial growth factor A -- CD31 Platelet endothelial cell adhesion molecule-1 -- ZO-1 Zonulaoccludens 1 -- NGF Nerve growth factor -- NT-3 Neurotrophin-3 -- TGF-β Transforming growth factor-β -- IL-10 Interleukin 10 -- CD86 Cluster of differentiation 86 -- Arg-1 Arginase 1 -- NF-200 Neurofilament-200 -- GFAP Glial fibrillary acidic protein -- DSPE-PEG2000 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] -- DiI 1-dioctadecyl-3, 3, 3, 3-tetramethylindocarbocyanine perchlorate -- BBB Basso-Beattie-Bresnahan; Materials science -- Periodicals; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; 620.1
• DOI: 10.1016/j.mtbio.2023.100546
• Languages: English
• ISSNs: 2590-0064

Abstract

Abstract: Nanoparticle technologies offer a non-invasive means to deliver basic fibroblast growth factor (bFGF) for the treatment of spinal cord injury (SCI). However, the inability of bFGF to accumulate at the injury site and inefficient penetration across the blood-spinal cord barrier (BSCB) remain challenges. The present study describes a dual-targeting liposome (bFGF@Lip-Cp&Rp) with injury lesion targeting and BSCB-penetrating capability to deliver bFGF for SCI treatment. The CAQK peptide (Cp) with injury lesion targeting ability and R2 KC peptide (Rp) with BSCB-penetrating capability were grafted onto the liposomes for a flexible and non-invasive drug delivery systems preparation. Results exhibit that the dual-targeted liposomes could significantly cross the BSCB and accumulate at the injury site. During the early stage of SCI, bFGF@Lip-Cp&Rp promotes repair of BSCB and facilitates M2-polarization of macrophages. Regular delivery of bFGF@Lip-Cp&Rp increase HUVECs tube formation and angiogenesis, ameliorate the microenvironment of lesion site, suppress the neuronal apoptosis and axonal atrophy in SCI rats. Importantly, continuous treatment of bFGF@Lip-Cp&Rp supports the restoration of limb motor function in SCI rats. In summary, this research implies that the injury site-targeting and BSCB-penetrating liposomes could be a promising therapeutic approach for the treatment of SCI. Graphical abstract: A bFGF-loaded dual-targeting liposome (bFGF@Lip-Cp&Rp) with injury lesion targeting and BSCB penetrating capability was constructed for spinal cord injury repair. Image 1 Highlights: A dual-targeted liposomes (bFGF@Lip-Cp&Rp) was prepared to deliver bFGF for SCI treatment. The bFGF@Lip-Cp&Rp shows injury lesion targeting and BSCB penetrating capability. The bFGF@Lip-Cp&Rp promotes BSCB repair, M2 macrophages polarization and angiogenesis. The bFGF@Lip-Cp&Rp promotes the recovery of motor function in SCI rats.